<DOC>
	<DOCNO>NCT01523171</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy daily dose SAR302503 subject previously treat ruxolitinib current diagnosis intermediate-1 symptom , Intermediate-2 high-risk primary myelofibrosis ( PMF ) , post-polycythemia vera myelofibrosis ( Post-PV MF ) , post-essential thrombocythemia myelofibrosis ( Post-ET MF ) base reduction spleen volume end 6 treatment cycle ; Secondary Objectives : - To evaluate effect SAR302503 Myelofibrosis ( MF ) associate symptom measure modified Myelofibrosis Symptom Assessment Form ( MFSAF ) diary - To evaluate durability splenic response - To evaluate splenic response SAR302503 palpation end Cycle 6 - To evaluate splenic response SAR302503 end Cycle 3 - To evaluate effect SAR302503 Janus kinase 2 ( JAK2 ) V617F allele burden - To evaluate safety tolerability SAR302503 population - To evaluate plasma concentration SAR302503 population PK analysis , warrant</brief_summary>
	<brief_title>Phase II , Open Label , Single Arm Study SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib</brief_title>
	<detailed_description>The expected duration treatment study approximately 8 month , base maximum 28-day screening period , follow 6-month ( 6-cycle ) treatment period , EOT visit subject continue treatment complete 6 cycle SAR302503 , discontinue treatment early reason well follow-up visit occur 30 day last administration SAR302503 . Patients continue benefit clinically allow remain study medication beyond 6-month treatment period occurrence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Diagnosis PMF PostPV MF PostET MF , accord 2008 World Health Organization IWGMRT response criterion Subjects previously receive Ruxolitinib treatment PMF PostPV MF PostET MF PV ET least 14 day ( exposure &lt; 14 day allow subject discontinue Ruxolitinib due intolerability allergy ) discontinue treatment least 14 day prior first dose SAR302503 MF classify Intermediate1 symptom , Intermediate2 highrisk Dynamic International Prognostic Scoring System ( Passamonti et al. , Blood 2010 ) Spleen ≥5 cm costal margin measure palpation Male female subject ≥18 year age Signed write informed consent Exclusion criterion : Splenectomy Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 first dose SAR302503 Cycle 1 Day1 The following laboratory value within 14 day prior initiation SAR302503 : Absolute Neutrophil Count ( ANC ) &lt; 1.0 x 10exp9/L Platelet count &lt; 50 x 10exp9/L Serum creatinine &gt; 1.5 x Upper limit normal ( ULN ) Serum amylase lipase &gt; 1.5 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥2.5 x ULN Total bilirubin ≥3.0 x ULN Subjects total bilirubin 1.53.0 x ULN must exclude direct bilirubin fraction ≥25 % total Subjects know active ( acute chronic ) Hepatitis A , B , C ; Hepatitis B C carrier Prior history chronic liver disease ( eg , chronic alcoholic liver disease , autoimmune hepatitis , sclerosing cholangitis , primary biliary cirrhosis , hemachromatosis , nonalcoholic steatohepatitis [ NASH ] ) Subjects prior malignancy eligible , except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject diseasefree least 5 year Any chemotherapy , immunomodulatory drug therapy ( eg , thalidomide , interferonalpha ) , Anagrelide , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( eg , erythropoietin ) , hormone ( eg , androgen , danazol ) within 14 day prior initiation SAR302503 ; darbepoetin use within 28 day prior initiation SAR302503.The chemotherapy allow hydroxyurea within 1 day prior initiation SAR302503 Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation SAR302503 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>